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Abstract
Here we report the case of a 54-year old, immunocompetent German patient with primary varicella whose Vari-
cella-Zoster Virus (VZV)-specific T-cell responses could be detected early in infection and before the onset of sero-
conversion. This case demonstrates that the detection of VZV-specific T-cells may under certain circumstances
support the diagnosis of a primary varicella infection, as for example in cases of atypical or subclinical varicella or
in the absence of detectable VZV DNA in plasma.
Background
Varicella-Zoster virus (VZV) causes varicella during pri-
mary infection and may cause herpes zoster after reacti-
vation from latency. Varicella is typically diagnosed by
characteristic clinical signs and usually does not require
laboratory testing. Due to the introduction of mass vac-
cination programmes, however, the incidence of typical
varicella has declined. This decline has led to a reduced
experience of physicians in diagnosing varicella. Further-
more, an increased incidence of atypical and vaccination
breakthrough varicella infections has been described
[1-4]. For the early diagnosis of cases with severe or aty-
pical varicella rapid VZV identification techniques are
indicated to initiate specific antiviral therapy. Serological
markers (i.e. VZV-IgM and/or VZV-IgG) are not appro-
priate for the laboratory diagnosis of early varicella,
because they are detectable in a time-delayed manner
[5]. Therefore, the method of choice for the rapid diag-
nosis of varicella is polymerase chain reaction (PCR) out
of specimen collected from les i o n s[ 6 ] .H e r ew er e p o r t
that the rapid diagnosis of an early varicella infection
m a ya l s ob ep o s s i b l eb yt h ed e t e c t i o no fV Z V - s p e c i f i c
CD4+ T-cells from peripheral blood.
Case presentation
We report the case of a 54-year-old, immunocompetent
German (Caucasian) man who presented with skin rash
and fever (day 0). Due to the clinical appearance of a
typical “varicella-like” rash phenotype, antiviral therapy
with Brivudine was initiated at the day of the patient’s
presentation and rash onset. Serological analysis of blood
taken at day 0 exhibited no VZV-specific antibodies indi-
cative for a past (VZV-IgG) or primary (VZV-IgM) VZV
infection. In order to confirm the suspicion of primary
varicella, a second blood sample was taken at day 2 post
rash onset (p.r.o.). Again, subsequent serological testing
for VZV-specific IgG and IgM antibodies exhibited nega-
tive results. However, abundant numbers of VZV-specific
CD4+ T-cells could be detected within this second sam-
ple. Analysis of VZV-specific T-cells was performed by a
novel in house flow cytometry assay after intracellular
interferon g staining of isolated and ex vivo stimulated
peripheral blood mononuclear cells (PBMCs). For a
detailed protocol see additional file 1: PDF document
describing our protocol for the detection of VZV-specific
T-cells. Detected VZV-specific CD4+ T-cell titers yielded
1% when VZV lysate was used for stimulation, and 0.73%
when utilizing recombinant glycoprotein E (gE). Apart
from detecting abundant numbers of VZV-specific
T-cells, primary varicella could also be diagnosed by
virus isolation from vesicular fluid and by quantitative
PCR for VZV-DNA out of vesicular fluid (Ct 16) or
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p.r.o.. Here, the respective VZV serology demonstrated
seroconversion with VZV-IgG titers of 2.2 IU/l and
VZV-IgM titers of 1:160. VZV-specific CD4+ T-cells
titers decreased to 0.19% when stimulating with VZV
lysate, and 0.17% when stimulating with recombinant gE.
A quantitative PCR for VZV-DNA performed out of
plasma was positive at low levels (Ct 39). A fourth and
final blood sample was taken at day 15 p.r.o.. The respec-
tive VZV serology revealed VZV-IgG titers of 2.4 IU/l
and VZV-IgM titers of 1:160. VZV-specific CD4+ T-cells
titers further decreased to 0.063% when stimulating with
VZV lysate, and 0.065% when stimulating with recombi-
nant gE. VZV-DNA in plasma could not be detected any
more by PCR at this stage. All relevant clinical and diag-
nostic parameters of the reported case are depicted in
Figure 1 (Fig. 1).
Conclusions
The development of novel assays for the detection of
virus-specific T-cells will contribute to answer a variety
of medically relevant questions that could so far not be
addressed sufficiently. Among them (a) the diagnosis of
a pathogen involvement if serological parameters are
impaired, (b) the differentiation between different stages
of viral infections, (c) the monitoring of the immune
status of immunosuppressed patients after solid organ
or bone marrow transplantation, (d) the examination of
vaccine efficiency with respect to cellular immunity, or
(e) the determination of immune correlates of protec-
tion towards a herpes zoster reactivation as indication
for zoster vaccination. Here we report that the detection
of VZV-specific T-cells may (f) additionally support the
rapid diagnosis of an early varicella infection before
seroconversion.
As to our knowledge, no systematic comparison
between the onset kinetics of seroconversion and occur-
rence of VZV-specific T-cells within patients at early
stages of varicella infection has been performed until
today. Seroconversion has been described to appear one
to seven days p.r.o. [7]. In contrast, activation of circu-
lating T lymphocytes has been reported to occur earlier,
in some patients already during the incubation
period [7,8].
Figure 1 Clinical and diagnostic parameters of the reported case. A 54-year-old Caucasian presented with “varicella-like” skin rash and fever
(day 0). Serological testing was negative for VZV-IgG (black circle) and VZV-IgM. A second blood sample was taken at day 2 p.r.o.. Serological
testing for VZV-specific IgG (black circle) and IgM antibodies exhibited negative results. Abundant numbers of VZV-specific (CD4+/IFNg+) T-cells
could be detected within this second sample. Detected VZV-specific T-cell frequencies yielded 1% (100 in 10000 CD4+ T cells) when VZV lysate
(Lysate) was used for stimulation (black bar), and 0.73% when utilizing recombinant glycoprotein E (rec.gE) (striped bar). Primary varicella could
be diagnosed by virus isolation from vesicular fluid (v.f.) and by quantitative PCR for VZV-DNA out of v.f. or plasma (pl.) with Ct 16 and Ct 36,
respectively. A third blood sample taken at day 6 p.r.o. demonstrated seroconversion with VZV-IgG titers of 2.2 IU/l (black circle) and VZV-IgM
titers of 1:160. VZV-specific T-cells frequencies decreased to 0.19% when stimulating with Lysate and 0.17% when stimulating with rec.gE.
Quantitative PCR for VZV-DNA out of plasma revealed Ct 39. A final blood sample taken at day 15 p.r.o. revealed VZV-IgG titers (black circle) of
2.4 IU/l and VZV-IgM titers of 1:160. VZV-specific T-cell frequencies further decreased to 0.063% when stimulating with Lysate, and 0.065% when
stimulating with rec.gE. Abbreviations: not assayed (n/a), post rash onset (p.r.o.), vesicular fluid (v.f.), plasma (pl.), cycle threshold numbers (Ct),
international units per liter as assayed by Siemens Enzygnost Anti-VZV/IgG (IU/l).
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IFNg+ T-cell titers were highest at day two p.r.o. and
before the occurrence of seroconversion. At this time,
titers of up to 1% of total CD4+ T-cells were detected.
Such elevated CD4+ T-cell titers have been described
during acute varicella infections [9]. The percentage of
VZV-specific CD4+ T-cells is declining steadily over
time, reaching levels of ~0.18% (± 0.01) at day six and
~0.064% (± 0.001) at day 15 p.r.o. (Fig. 1). The latter
T-cell titers are slightly above those described for
VZV-specific memory (<0.01%) [10]. No significant
increase in IgG titers could be observed within our
patient between day 6 (2.2 IU/l) and day 15 (2.4 IU/l),
which could be explained by the early initiation of anti-
viral therapy at the day of rash onset.
We conclude that the analysis of VZV-specific CD4+
T-cells might support the rapid diagnosis of primary
varicella under certain circumstances, as for example in
cases of atypical or subclinical varicella or in the
absence of detectable VZV DNA in plasma.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
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Additional file 1: Protocol for the detection of VZV-specific T-cells:
This additional file provides a detailed protocol for the detection of VZV-
specific T-cells from heparinized blood.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-54-
S1.PDF]
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